Ginkgo Bioworks Holdings Operating Income 2020-2022 | DNA

Ginkgo Bioworks Holdings annual/quarterly operating income history and growth rate from 2020 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Ginkgo Bioworks Holdings operating income for the quarter ending March 31, 2022 was $-0.675B, a 1080.98% increase year-over-year.
  • Ginkgo Bioworks Holdings operating income for the twelve months ending March 31, 2022 was $-2.446B, a 2572.26% increase year-over-year.
  • Ginkgo Bioworks Holdings annual operating income for 2021 was $-1.828B, a 1234.38% increase from 2020.
  • Ginkgo Bioworks Holdings annual operating income for 2020 was $-0.137B, a 91.38% increase from 2019.
  • Ginkgo Bioworks Holdings annual operating income for 2019 was $-0.072B, a INF% decline from .
Ginkgo Bioworks Holdings Annual Operating Income
(Millions of US $)
2021 $-1,828
2020 $-137
2019 $-72
Ginkgo Bioworks Holdings Quarterly Operating Income
(Millions of US $)
2022-03-31 $-675
2021-12-31 $-1,739
2021-09-30 $-27
2021-06-30 $-5
2021-03-31 $-57
2020-12-31
2020-09-30 $-34
2019-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.223B $0.314B
Ginkgo Bioworks platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks, formerly known as Soaring Eagle Acquisition Corp., is based in NEW YORK.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.407B 10.06
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.180B 16.07
Biohaven Pharmaceutical Holding (BHVN) United States $10.170B 0.00
Arcus Biosciences (RCUS) United States $1.792B 45.42
Emergent Biosolutions (EBS) United States $1.625B 6.95
Myovant Sciences (MYOV) United Kingdom $1.313B 0.00
Zymeworks (ZYME) Canada $0.365B 0.00
Gelesis Holdings (GLS) United States $0.122B 0.00
Ambrx Biopharma (AMAM) United States $0.110B 0.00
Enzo Biochem (ENZ) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00